Evidence map›Paper›PMID 33658555›Full record

ArticleScientific reports2021

Expression of inflammatory interleukins and selected miRNAs in non-small cell lung cancer.

Agata Dutkowska, Bartosz Szmyd, Marcin Kaszkowiak, Daria Domańska-Senderowska, Dorota Pastuszak-Lewandoska, Ewa Brzeziańska-Lasota, Jacek Kordiak, Adam Antczak

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Therapeutic Significance of NLRP3 Inflammasome in Cancer: Friend or Foe?International journal of molecular sciences · 2024
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Agata DutkowskaDepartment of General and Oncological Pulmonology, Medical University of Lodz, Lodz, Poland. agata.dutkowska@umed.lodz.pl.
Bartosz SzmydDepartment of Biomedicine and Genetics, Medical University of Lodz, Lodz, Poland.
Marcin KaszkowiakDepartment of Biomedicine and Genetics, Medical University of Lodz, Lodz, Poland.
Daria Domańska-SenderowskaDepartment of Biomedicine and Genetics, Medical University of Lodz, Lodz, Poland.
Dorota Pastuszak-LewandoskaDepartment of Microbiology and Laboratory Medical Immunology, Lodz, Poland.
Ewa Brzeziańska-LasotaDepartment of Biomedicine and Genetics, Medical University of Lodz, Lodz, Poland.
Jacek KordiakDepartment of Chest Surgery, General and Oncological Surgery, University Teaching Hospital No. 2, Medical University of Lodz, Lodz, Poland.
Adam AntczakDepartment of General and Oncological Pulmonology, Medical University of Lodz, Lodz, Poland.
Medical University of Lodz · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumours are characterised by an ability to avoid immune destruction and the presence of cancer-associated inflammation. Better understanding of the link between lung cancer and such inflammation is vital for early detection and personalized treatment. Thus, we examined the mRNA expression of interleukins IL-1β, IL-6, IL-17 and miR-9, miR-122 as potential useful biomarkers of NSCLC. Tumour tissues, non-cancerous tissue and blood samples were collected from 39 patients with primary NSCLC undergoing surgical treatment. The selected RNA was isolated from tissue samples and selected miRNAs from peripheral blood exosomes. This RNA was transcribed to cDNA and quantified using RT-qPCR. Significantly higher expression of the selected interleukins was observed in non-cancerous than tumour tissue, and IL-6 was significantly higher in the tumour tissue of patients with a history of ≤ 40 pack-years (PYs) (2.197, IQR: 0.821-4.415) than in those with > 40 PYs (0.461, IQR: 0.372-0.741; p = 0.037). It is clear that inflammatory processes play a role in NSCLC, as indicated by the upregulation of IL-1β and IL-6 in tumour and adjacent tissue, and that smoking has a strong influence on inflammation in tumourigenesis, demonstrated by the upregulation of IL-6 in tumour samples among patients with ≤ 40 PYs compared to > 40 PYs.

Indexed as

Gene ExpressionAdenocarcinoma of LungAgedBiomarkers, TumorCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellFemaleGene Expression Regulation, NeoplasticHumansInterleukin-17Interleukin-1betaInterleukin-6Lung NeoplasmsMaleMicroRNAsMiddle AgedBiomarkers, TumorIL17A protein, humanIL1B protein, humanIL6 protein, humanInterleukin-17Interleukin-1betaInterleukin-6MicroRNAsMIRN122 microRNA, humanMIRN92 microRNA, human

Identifiers

PMID33658555
PMCPMC7930048
OpenAlexW3134126417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.